Equity Profile

RMD

ResMed Inc.

Health CareHealth Care Equipment$32.9B

Aug6Thu

Pre-Earnings Brief

UpcomingQ4-2026After Close5:00 PM EDT

Company Snapshot

ResMed Inc. is a health care company focused on developing equipment related to sleep disorders and respiratory conditions....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Expected to be around $2.86.

Revenue Growth

Revenue growth reflects the company's ability to expand its market share and product offerings, crucial for long-term sustainability.

Not available.

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

RMD Q4-2026 Earnings Preview

Context

Company Snapshot

ResMed Inc. is a health care company focused on developing equipment related to sleep disorders and respiratory conditions. With a market cap of $33 billion, it plays a significant role in the health care equipment sector, which is increasingly important as global health awareness rises.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+3.72%

Avg Stock Reaction

+0.21%

Last Quarter Recap

In Q3-2026, ResMed reported an EPS of $2.86, beating expectations by 2.58%. The stock reacted positively, gaining 0.89% the following day.

Management Promises & Guidance

Continued focus on innovation in sleep and respiratory care.
Commitment to expanding market presence in emerging regions.
Enhancements in product offerings to meet customer needs.

Expectations

Wall Street Expectations

Overall, analysts expect ResMed to maintain its strong performance, particularly in EPS. However, concerns about revenue growth and market competition remain.

Bull Case

If ResMed continues to innovate and capture market share, it could see substantial revenue growth and further EPS beats.

Bear Case

On the other hand, if market demand slows or competition increases significantly, it could lead to disappointing results and a decline in stock value.

Key Metrics to Watch

Earnings Per Share (EPS)

Expected to be around $2.86.

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue Growth

Not available.

Revenue growth reflects the company's ability to expand its market share and product offerings, crucial for long-term sustainability.

Market Demand for Sleep Apnea Devices

Not available.

As sleep disorders become more recognized, demand for ResMed's products may significantly impact revenue.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected EPS for the upcoming quarter?

Given the company's history of beating EPS estimates, this will be a critical indicator of ongoing profitability.

How is demand for sleep apnea devices trending?

Understanding market demand will help gauge future revenue potential and the company's competitive position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the impact of emerging markets on ResMed's growth potential, which could lead to higher-than-expected revenue.

Supporting Evidence

Recent trends show increasing awareness and diagnosis of sleep disorders in developing regions.

Options pricing indicates a significant expected move, suggesting traders anticipate volatility that may not be fully reflected in consensus estimates.

Key Risk

If demand for sleep apnea devices exceeds expectations, it could lead to a significant upward revision of future earnings forecasts.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is keenly focused on EPS and demand trends, which are pivotal for ResMed's growth narrative.

Bull Confirmed If

An EPS of $2.90 or higher would confirm strong demand and effective cost management.

Bear Confirmed If

An EPS below $2.80 could signal weakening demand or increased competition.

Pre-Earnings Positioning

Options Market

Implied Move

±5.12%

Historical Avg

±0.9%

Pricing rich

The options market is pricing in a potential move of over 5%, indicating that traders expect significant volatility around the earnings report.

Options are pricing ±5.1% while RMD has averaged ±0.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

31.1%

Calls (4K)P/C Ratio: 0.65Puts (155K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If ResMed beats expectations, history suggests the stock could rise by about 0.21% on the first day, confirming strong market performance.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further commentary from management.

Miss

A miss could lead to a decline, potentially around 0.54%, as investors reassess growth prospects.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches in sleep and respiratory care.
2Management's commentary on market expansion efforts in emerging markets.
3Insights into competitive pressures and how ResMed plans to address them.
4Trends in customer demand for sleep apnea devices and other key products.
5Any changes in guidance or outlook for the upcoming quarters.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

ResMed Inc. is a health care company focused on developing equipment related to sleep disorders and respiratory conditions....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Expected to be around $2.86.

Revenue Growth

Revenue growth reflects the company's ability to expand its market share and product offerings, crucial for long-term sustainability.

Not available.

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

RMD Q4-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+3.72%

Avg Stock Reaction

+0.21%

Last Quarter Recap

In Q3-2026, ResMed reported an EPS of $2.86, beating expectations by 2.58%. The stock reacted positively, gaining 0.89% the following day.

Management Promises & Guidance

Continued focus on innovation in sleep and respiratory care.
Commitment to expanding market presence in emerging regions.
Enhancements in product offerings to meet customer needs.

Expectations

Wall Street Expectations

Overall, analysts expect ResMed to maintain its strong performance, particularly in EPS. However, concerns about revenue growth and market competition remain.

Bull Case

If ResMed continues to innovate and capture market share, it could see substantial revenue growth and further EPS beats.

Bear Case

On the other hand, if market demand slows or competition increases significantly, it could lead to disappointing results and a decline in stock value.

Key Metrics to Watch

Earnings Per Share (EPS)

Expected to be around $2.86.

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue Growth

Not available.

Revenue growth reflects the company's ability to expand its market share and product offerings, crucial for long-term sustainability.

Market Demand for Sleep Apnea Devices

Not available.

As sleep disorders become more recognized, demand for ResMed's products may significantly impact revenue.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected EPS for the upcoming quarter?

Given the company's history of beating EPS estimates, this will be a critical indicator of ongoing profitability.

How is demand for sleep apnea devices trending?

Understanding market demand will help gauge future revenue potential and the company's competitive position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the impact of emerging markets on ResMed's growth potential, which could lead to higher-than-expected revenue.

Supporting Evidence

Recent trends show increasing awareness and diagnosis of sleep disorders in developing regions.

Options pricing indicates a significant expected move, suggesting traders anticipate volatility that may not be fully reflected in consensus estimates.

Key Risk

If demand for sleep apnea devices exceeds expectations, it could lead to a significant upward revision of future earnings forecasts.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is keenly focused on EPS and demand trends, which are pivotal for ResMed's growth narrative.

Bull Confirmed If

An EPS of $2.90 or higher would confirm strong demand and effective cost management.

Bear Confirmed If

An EPS below $2.80 could signal weakening demand or increased competition.

Pre-Earnings Positioning

Options Market

Implied Move

±5.12%

Historical Avg

±0.9%

Pricing rich

The options market is pricing in a potential move of over 5%, indicating that traders expect significant volatility around the earnings report.

Options are pricing ±5.1% while RMD has averaged ±0.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

31.1%

Calls (4K)P/C Ratio: 0.65Puts (155K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If ResMed beats expectations, history suggests the stock could rise by about 0.21% on the first day, confirming strong market performance.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further commentary from management.

Miss

A miss could lead to a decline, potentially around 0.54%, as investors reassess growth prospects.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches in sleep and respiratory care.
2Management's commentary on market expansion efforts in emerging markets.
3Insights into competitive pressures and how ResMed plans to address them.
4Trends in customer demand for sleep apnea devices and other key products.
5Any changes in guidance or outlook for the upcoming quarters.